During my PhD studies at Sanquin Research we discovered a novel antibody directed against complement regulator factor H (FH) with an intriguing effect on FH functionality. Following our initial discovery of one antibody, we identified additional antibodies with similar function during my Junior Post-doctoral period a Sanquin Research. We demonstrated that these antibodies improve the function of native FH and even restore the function of mutated FH in vitro (Pouw et al. 2019, Dekkers et al. 2020). These antibodies could provide a new therapeutic option for complement-mediated disease in which FH function is diminished, such as in atypical hemolytic uremic syndrome (aHUS). The antibodies were patented and are currently being further developed by Gemini Therapeutics.
Pouw RB, Brouwer MC, Wouters D, Kuijpers TW. Factor H potentiating antibodies and uses thereof. WO2016028150A1 – priority date 2014-08-20 – Approved (USA) 2018-10-30
Pouw RB, Brouwer MC, Wouters D, Kuijpers TW. Factor H potentiating antibodies and uses thereof. WO2019139481A1 – priority date 2018-01-15
